Although we are unable to substantiate the in vitro studies suggesting a role for c-Src in tamoxifen resistance we feel that further clarification defining the role of c-Src in the different subtypes of breast cancer, particularly in ER-negative breast cancer and recurrent tumours, is warranted as this likely represents the group in which targeted Src Kinase inhibition may be beneficial to patient outcome. Here, SRC is linked to breast carcinoma.